Growth Hormone · 5mg × 10 vials
In plain terms: GHRP-2 is a research compound - oral, fast-acting and well studied.
GHRP-2 (pralmorelin, hexapeptide D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2) is a synthetic growth hormone secretagogue that binds the ghrelin receptor (GHS-R1a) on pituitary somatotrophs and triggers a pulse of growth hormone release. Mechanistically it sits in the same class as ipamorelin, GHRP-6, and hexarelin: each is a GHS-R1a agonist that fires a calcium/phospholipase-C signal cascade at the pituitary, producing a sharp GH pulse independent of GHRH tone but additive with it (the Bowers synergy effect). Where GHRP-2 differs is selectivity tradeoff. On a per-microgram basis it is the second-most-potent GHRP for GH release (behind hexarelin, ahead of GHRP-6 and ipamorelin), but it is NOT selective the way ipamorelin is. GHRP-2 also activates ACTH/cortisol release and modestly elevates prolactin in a dose-dependent way (10-15% cortisol bump at 100 mcg, 25-35% at 200-300 mcg), and it produces an appetite signal that sits between ipamorelin (essentially none) and GHRP-6 (intense ghrelin-style hunger).
The practical positioning is "middle of the GHRP road". GHRP-2 gives more raw GH pulse than ipamorelin (the published GH peak data favors GHRP-2 at matched dose), less appetite stimulation than GHRP-6 (the 1998-2005 food-intake studies show GHRP-2 raised intake but well under GHRP-6's signal), and less cortisol/prolactin than hexarelin plus far less tachyphylaxis. Stacked with a GHRH analog (CJC-1295 no-DAC, mod GRF 1-29, or tesamorelin) it produces GH responses 3-5x larger than either compound alone, same Bowers effect that drives the CJC+Ipa blend, except the GHRP-2 side hits stronger than the ipamorelin side. Regulatory note: GHRP-2 (as pralmorelin) reached Phase II in the US/EU as a therapeutic for adult and pediatric GH deficiency but was abandoned because it underperformed in actual GHD patients (the diseased pituitary doesn't respond as well as the healthy one). It WAS approved in Japan in 2004 by Kaken Pharmaceutical as a single-dose diagnostic for GH deficiency, which is still its only standing regulatory approval anywhere. No FDA approval exists, and no formal FDA orphan designation appears in current literature; the regulatory story is Japan-only.
Typical dose ranges by experience level - educational reference. Message us and we tailor it to you.
100 mcg is the dose band where cortisol/prolactin elevation stays minimal per the published dose-response data (the 10-15% cortisol bump at 100 mcg vs 25-35% at 200-300 mcg). Beginners running GHRP-2 should hold at this band to keep the cortisol side clean. 5 mg vial (G25) recon'd with 2 ml BAC = 2.5 mg/ml; at 100 mcg twice daily, one vial lasts 25 days. The 10 mg vial (G210) lasts twice as long. Pre-bed is the highest-leverage shot.
The "working dose" band. Stacking with a GHRH analog (CJC-1295 no-DAC or mod GRF 1-29 at 100 mcg per shot) at the same windows produces the 3-5x GH amplification (Bowers synergy). Most intermediate GHRP-2 users are running it stacked rather than solo, because solo GHRP-2 wastes the strongest feature of the compound (the synergy). Three-times-daily dosing matches natural GH physiology best, three distinct pulses spread across the day.
At the advanced band the cortisol/prolactin signal is no longer trivial: cortisol elevation runs 25-35% above baseline at 200-300 mcg per shot per multiple human studies. Advanced GHRP-2 users either accept that tradeoff for the stronger GH pulse or rotate with ipamorelin every 4-6 weeks to give the cortisol axis a rest. Always stacked with CJC-1295 no-DAC at this band, not solo.
Straight talk - what people actually report, and what the studies measured.
Peer-reviewed studies and clinical guidelines - tap any to read the source.
:975-982](https://pubmed.ncbi.nlm.nih.gov/2156870/) - foundational synergy demonstration showing co-administration produces GH response exceeding sum of parts, the rationale for stacking GHRP-2 with a GHRH analog
Read study ↗PubMedPralmorelin development summary, PMID 15230633Kaken Pharmaceutical development, Phase II abandonment for therapeutic GHD, Japan diagnostic approval pathway
Read study ↗PubMedBowers CY et al, On the actions of the growth hormone-releasing hexapeptide, GHRP, Endocrinology 1984original characterization of the GHRP class
Read study ↗PubMedGHRP-2 antinociceptive effects via opioid receptor in mice, ScienceDirectghrelin agonist mechanism characterization beyond GH axis
Read study ↗PubMedAnti-inflammatory effect of GHRP-2 in arthritic rats, Am J Physiol Endocrinol Metaboff-target ghrelin-receptor effects
Read study ↗Clinical guidelinesPralmorelin (GHRP-2) WikipediaWikipedia](https://en.wikipedia.org/wiki/Pralmorelin) - Japan approval (Kaken 2004), Phase II therapeutic abandonment for GHD, pioneering GHS class status
Read study ↗Aggregated sentiment from public forums & socials - real-world reports, not individual endorsements.
Better sleep within 5-10 days: most-reported positive effect from pre-bed dosing, deeper sleep and more vivid dreams
Hunger bump in the 20-30 min window after injection: clearly noticeable, sharper than ipamorelin reports, milder than GHRP-6 reports per community comparison threads. Users who've run both confirm GHRP-2 is the "manageable hunger" middle ground.
Mild anxiety / "wired" feeling at higher doses: tracks the cortisol bump, more reported above 200 mcg per shot, settles back if dose is dropped
Water retention and slight puffiness: especially first 2-3 weeks, settles
Slight fat loss around the waist + visible lean fullness: typical reports by week 8-12 when stacked with CJC, weaker reports for solo GHRP-2
Skin quality, hair growth, faster workout recovery: common reports by week 4-6
Route: SubQ (subcutaneous injection into abdominal fat or outer thigh)
Injection site: abdomen pinch (around the navel, 2 inches out) or outer thigh, rotate sites each shot, fresh insulin syringe each time
Storage: refrigerated, ~30 days after reconstitution. Unreconstituted vials stable at room temp short-term, refrigerate long-term. Don't freeze reconstituted vials.
Notes: Inject on an empty stomach. Food (especially carbs and fats) blunts the GH pulse via insulin's suppressive effect on GH release and free-fatty-acid suppression of pituitary response. Standard windows are first thing AM fasted, pre-workout 30-45 min before training, and pre-bed at least 2 hours after last meal. Pre-bed shot is the highest-leverage one because it stacks with the natural slow-wave-sleep GH pulse. Inject BAC slowly down the vial wall, swirl gently, don't shake. The GH pulse peaks 15-30 min post-injection and clears within roughly 60-90 minutes given the ~20-30 min plasma half-life, which is why protocols call for 2-3 shots daily rather than once.